Current Report Filing (8-k)
January 06 2023 - 8:50AM
Edgar (US Regulatory)
0000882361
false
0000882361
2023-01-06
2023-01-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January
6, 2023
APTOSE
BIOSCIENCES INC.
(Exact
name of registrant as specified in its charter)
Canada |
001-32001 |
98-1136802 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
251
Consumers Road, Suite
1105
Toronto, Ontario,Canada M2J4R3
(Address
of Principal Executive Offices) (Zip Code)
(647) 479-9828
(Registrant's
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common
Shares, no par value |
APTO |
NASDAQ Capital
Market |
Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 9.01.
Financial Statements and Exhibits.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Aptose Biosciences Inc. |
|
|
|
|
|
|
Date: January 6, 2023 |
By: |
/s/ William G. Rice, Ph.D. |
|
|
William G. Rice, Ph.D. |
|
|
Chairman, President and Chief Operating Officer |
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Jul 2023 to Jul 2024